Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma

PURPOSE: To characterize the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme-inducing antiepileptic drugs (EIAED) compared with patients receiving non-EIAEDs. An additional objective was to determine whether concentrations of temsirolimus or sirolim...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Kuhn, John G., Chang, Susan M., Wen, Patrick Y., Cloughesy, Timothy F., Greenberg, Harry, Schiff, David, Conrad, Charles, Fink, Karen L., Robins, H. Ian, Mehta, Minesh, DeAngelis, Lisa, Raizer, Jeffrey, Hess, Kenneth, Lamborn, Kathleen R., Dancey, Janet, Prados, Michael D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4918812/
https://ncbi.nlm.nih.gov/pubmed/18094423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-07-0781
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller